Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Better Late Than Never: Efavirenz Dose Optimization

After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.

Published
03 April 2014
From
Treatment Action Group
Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

The updated guidelines include recommendations for use of newer antiretroviral drugs, including those in new classes, such as CCR5 receptor antagonists and integrase inhibitors. The new guidelines provide additional recommendations regarding use of rifampin with antiretroviral therapy; these recommendations are critical in regions where rifabutin is unavailable.

Published
31 March 2014
From
Morbidity and Mortality Weekly Report
Malnutrition decreases effectiveness of HIV treatment in pregnant African women

In Uganda the prescription of three antiretroviral drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.

Published
19 February 2014
From
Eurekalert Medicine & Health
High incidence of antiretroviral prescribing errors in Nigeria

Antiretroviral prescribing errors are common in Nigeria, according to results of a large prospective study published in PLOS ONE. Errors were detected in the prescriptions of almost all

Published
07 February 2014
By
Michael Carter
Victrelis (boceprevir) label changes update contraindications and drug interactions

On January 17, 2014, FDA approved changes to the Victrelis (boceprevir) package insert to expand the list of contraindicated medications and update the Drug Interaction section.

Published
23 January 2014
From
FDA
Risk of Harmful Drug Interactions Rises With Age in HIV+ US Group

Every 10 years of age independently raised chances that a person in a US HIV cohort would be prescribed an antiretroviral and a nonantiretroviral that should not be given together. One third of cohort members were prescribed medications with moderate or high evidence of a possible drug-drug interaction.

Published
26 November 2013
From
International AIDS Society
Ritonavir the cause of the interaction between telaprevir and ritonavir-boosted atazanavir

Ritonavir is the cause of the detrimental bi-directional interaction between telaprevir and ritonavir-boosted atazanavir, according to Spanish research published in the online edition of Clinical Infectious Diseases. The research involved

Published
25 November 2013
By
Michael Carter
Merck plans phase III study of once-daily raltegravir (Isentress)

The poster presentation A Single Dose Food Effect Study of Raltegravir Formulations (Poster #PE10/17) will be presented Thursday, Oct. 17, and Friday, Oct. 18, from 12:00 p.m. to 2:00 p.m. CET. Based on the results of this study and other data, Merck plans to initiate a Phase III clinical study on a once daily dosing regimen of ISENTRESS in early 2014, pending review by regulatory agencies. ISENTRESS is administered twice daily, in accordance with the approved Prescribing Information.

Published
16 October 2013
From
Merck press release
Studies look at community vs hospital-based HIV care and medication issues

HIV-positive people treated at community clinics were more likely to continue receiving care, while those treated at hospital clinics were more likely to maintain undetectable viral load,

Published
07 October 2013
By
Liz Highleyman
European Commission Approves Gilead Sciences' Tybost(TM), a New Boosting Agent for HIV Therapy

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Tybost(TM) (cobicistat 150 mg tablets), a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection.

Published
26 September 2013
From
Gilead press release
← First12345...17Next →

Filter by country